Related Experiment Videos
Idarubicin-anti-CD3 reduces vascular disease in mouse cardiac allografts
P L Mottram1, W Han, L Murray-Segal
1University of Melbourne, Department of Surgery, Royal Melbourne Hospital, Victoria, Australia.
Transplantation Proceedings
|March 20, 1999
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Design of peptide-based vaccines for cancer.
Current medicinal chemistry·2006
LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.
Transplant immunology·2001
MUC1 and breast cancer.
Current opinion in molecular therapeutics·2001
Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.
European journal of immunology·2000
Ten-Year Outcomes of Early Suboptimal Graft Function Following Deceased Donor Kidney Transplantation.
Transplantation proceedings·2026
Survival of Hepatocellular Carcinoma After Liver Transplantation: Validation of Malatya Criteria.
Transplantation proceedings·2026
Risk Factors for Acute Kidney Injury After Conventional Open Liver Transplantation: A Single-Center Retrospective Cohort Study.
Transplantation proceedings·2026
Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.
Molecular neurodegeneration advances·2026
Immune checkpoint blockade reshapes drug-associated toxicity: a pharmacovigilance atlas of drug-ICI interactions.
medRxiv : the preprint server for health sciences·2026
Predicting Neoantigen Immunogenicity from In Vivo Immune Editing.
bioRxiv : the preprint server for biology·2026
Cross-species spatial profiling links progranulin to an immune suppressive niche in brain metastasis.
bioRxiv : the preprint server for biology·2026